• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Vote for Thomson Reuters' Top BioPharma Deals of the Year


May 16, 2016.

The Intellectual Property & Science business of Thomson Reuters announced the nominees for the Allicense 2016 Breakthrough Awards, honoring the leading deals of 2015 in Biopharmaceutical Licensing and in Mergers and Acquisitions (M&A).

The awards-to be determined by public vote-will be presented on Wednesday, June 8 at Allicense in San Francisco, CA. 

This year’s nominees include five contenders in each of the two categories. Members of the biopharmaceutical community are invited to vote for the top breakthrough deals in each category until 3:45 PM on Wednesday, June 8.

The nominees are:


Licensee & Licenser


Vertex Pharmaceuticals and CRISPR Therapeutics

CRISPR-Cas9 gene editing technology to discover and develop new treatment for genetic diseases

Gilead Sciences and Galapagos

Galapagos' filgotinib targeting rheumatoid arthritis and inflammatory disease

Pfizer and Heptares Therapeutics

Develop novel drugs targeting GPCR against therapeutic indications

AstraZeneca/Medlmmune and Innate Pharma

IPH2201, an anti-NKG2A humanized IgG4 antibody in immuno-oncology

Sanofi/Genzyme and Voyager Therapeutics

Adeno-associated viral (AAV) gene therapies for severe CNS disorders





Alexion Pharmaceuticals

Synageva BioPharma


Acerta Pharma

Bristol-Myers Squibb

Cardioxyl Pharmaceuticals

Roche Pharma

Foundation Medicine


Quanticel Pharmaceuticals




Related Videos
Related Content